Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25189853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Behshid Ghadrdoost Nakhchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Versiti Blood Research Institute, Milwaukee, WI 53226, USA. Hauptthemen laut MEDLINE: Neoplasms, rap GTP-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, And Blood Institute of the National Institutes of Health.
Abstract (Originalsprache)
The vascular endothelium, a specialized monolayer of endothelial cells (ECs), is crucial for maintaining vascular homeostasis by controlling the passage of substances and cells. In the tumor microenvironment, Vascular Endothelial Growth Factor A (VEGF-A) drives tumor angiogenesis, leading to endothelial anergy and vascular immunosuppression—a state where ECs resist cytotoxic CD8+ T cell infiltration, hindering immune surveillance. Immunotherapies have shown clinical promise. However, their effectiveness is significantly reduced by tumor EC anergy. Anti-angiogenic treatments aim to normalize tumor vessels and improve immune cell infiltration. Despite their potential, these therapies often cause significant systemic toxicities, necessitating new treatments. The small GTPase Rap1B emerges as a critical regulator of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) signaling in ECs. Our studies using EC-specific Rap1B knockout mice show that the absence of Rap1B impairs tumor growth, alters vessel morphology, and increases CD8+ T cell infiltration and activation. This indicates that Rap1B mediates VEGF-A’s immunosuppressive effects, making it a promising target for overcoming vascular immunosuppression in cancer. Rap1B shares structural and functional similarities with RAS oncogenes. We propose that targeting Rap1B could enhance therapies’ efficacy while minimizing adverse effects by reversing endothelial anergy. We briefly discuss strategies successfully developed for targeting RAS as a model for developing anti-Rap1 therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Versiti Blood Research Institute, Milwaukee, WI 53226, USA.
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
- Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Ramoji Kosuru, Magdalena Chrzanowska
Förderung
- NHLBI NIH HHS
- National Heart, Lung, And Blood Institute of the National Institutes of Health
Zitieren
APA
Ghadrdoost Nakhchi, B., Kosuru, R., & Chrzanowska, M. (2024). Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25189853
Vancouver
Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25189853
BibTeX
@article{GhadrdoostNakhchi2024,
author = {Ghadrdoost Nakhchi, Behshid and Kosuru, Ramoji and Chrzanowska, Magdalena},
title = {Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25189853}
}
EUVIMED